Interestingly patients with ERα-negative/ERβ-positive breast cancers are associated with increased survival compared to patients with ERα-negative/ERβ-negative breast cancers [41], suggesting that these ERα-negative patients would benefit from tamoxifen treatment. The gene discussed is ESR2; the disease is breast cancer.